search
Back to results

Trial on Outpatients With Systemic Sclerosis Treated With Well-Being Therapy or With a Control Therapy

Primary Purpose

Systemic Sclerosis

Status
Recruiting
Phase
Not Applicable
Locations
Italy
Study Type
Interventional
Intervention
Well-Being Therapy
Control condition
Sponsored by
University of Florence
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Systemic Sclerosis focused on measuring systemic sclerosis, well-being, psychological distress, suffering, mental pain, well-being therapy, psychotherapy

Eligibility Criteria

18 Years - 75 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. able and interested in participating to the research, as proved by signed Informed consent;
  2. a diagnosis of SSc (limited or diffuse) according to LeRoy et al. (1998);
  3. age higher than 18 years

Exclusion Criteria:

  1. co-occurrence of psychiatric disorder(s) according to the Diagnostic and Statistical Manual of mental disorders, 5th edition (American Psychiatric Association, 2013) as diagnosed via the Mini-International Neuropsychiatric Interview;
  2. currently under psychotherapy;
  3. change of the pharmacological treatment (including psychotropic medications) during the last three months.
  4. any other condition that, according to the Investigators' opinion, may alter the ability of the patient to follow study procedures.

Sites / Locations

  • Rheumtoi Unit, Academic Hospital CareggiRecruiting
  • Fiammetta CosciRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Placebo Comparator

Arm Label

Well-being therapy

Control condition

Arm Description

WBT will be used as the only non-pharmacological therapeutic strategy and 8 sessions will be delivered every other week with a duration of 60 minutes each. The manualized WBT will be used (Fava, 2016). Thus, the initial phase will be concerned with self-observation of psychological well-being. Once the instances of well-being will be properly recognized, the patient will be encouraged to identify thoughts, beliefs, and behaviors leading to premature interruption of well-being (intermediate phase). The final part will involve cognitive restructuring of dysfunctional dimensions of psychological well-being and meeting the challenge that optimal experiences may entail.

The control condition will include 8 every other week sessions based on Lifestyle and well-being National Institute for health and Care Excellence (NICE) guidelines (https://www.nice.org.uk/guidance/lifestyle-andwellbeing) and on World Health Organization 12 steps to healthy eating (http://www.euro.who.int/en/ health-topics/disease-prevention/nutrition/a-healthylifestyle). These sessions will inform participants about well-being and lifestyles which can influence it.

Outcomes

Primary Outcome Measures

Disability due to systemic sclerosis
The primary outcome will be the level of disability due to systemic sclerosis, assessed via the Health Assessment Questionnaire Disability Index (minimum: 0, maximum: 40, the highest the score the highest the level of disability).

Secondary Outcome Measures

Psychiatric status
Psychiatric status assessed via the Mini-International Neuropsychiatric Interview (no score applicable)
Psychosomatic status
Diagnostic Criteria for Psychosomatic Research-Revised Semi-Structured Interview (no score applicable)
Well-being
World Health Organization-Five Well-Being Index (min: 0, max: 25, the highest score corresponds to the lowest level of well-being)
Psychological well-being
the Psychological Well-Being Questionnaire (min: 0, max: 504, the highest score corresponds to the highest level of psychological well-being)
Euthymia
Euthymia Scale (min: 0, max: 60, the highest score corresponds to highest level of euthymia)
Suffering
Pictorial Representation of Illness and Self-Measure (min: 0, max: 30, the highest score corresponds to the lowest level of suffering)
Psychological distress
Symptom Questionnaire (min: 0, max: 92, the highest score corresponds to the highest level of psychological distress)
Pain in the body
Brief Pain Inventory (min: 0, max: 70, the highest score corresponds to highest level of pain)
Mental pain
Mental Pain Questionnaire (min: 0, max: 20, the highest score corresponds to the highest level of mental pain)
Psychiatric symptoms
Symptom Checklist-90-Revised (min: 0, max: 320, the highest score corresponds to the highest level of symptoms severity)
Harmony
Visual analouge scale (min: 0, max: 100, the highest score corresponds to the highest level of harmony)

Full Information

First Posted
December 18, 2019
Last Updated
May 16, 2022
Sponsor
University of Florence
search

1. Study Identification

Unique Protocol Identification Number
NCT04212247
Brief Title
Trial on Outpatients With Systemic Sclerosis Treated With Well-Being Therapy or With a Control Therapy
Official Title
Randomized Controlled Trial for Testing the Efficacy of Well-Being Therapy in Patients With Systemic Sclerosis
Study Type
Interventional

2. Study Status

Record Verification Date
May 2022
Overall Recruitment Status
Recruiting
Study Start Date
June 1, 2020 (Actual)
Primary Completion Date
October 31, 2023 (Anticipated)
Study Completion Date
October 31, 2023 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
University of Florence

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
Systemic sclerosis (SSc) is a rare and potentially life-threatening autoimmune disorder with a significant impact on health and quality of life. The non-pharmacological interventions address to psychological sequalae currently available are limited and have poor efficacy. Well-Being Therapy (WBT) is a brief psychotherapy which has shown efficacy in decreasing the relapse rates of depression in adults, in generalized anxiety disorder and in cyclothymia. WBT has never been tested in SSc and it might represent a useful complementary therapeutic option to improve SSc patients' well-being. The aim of the present study is to evaluate the psychological status of the SSc patients and to test the efficacy of WBT in a sample of SSc patients if compared to a control condition.
Detailed Description
Systemic sclerosis (SSc) is a rare, multisystem, chronic autoimmune connective tissue disease characterized by fibrosis of the skin and internal organs, skin thickening, and decreased organ functioning leading to dermatologic, vascular, pulmonary, cardiac, gastrointestinal, neurological, musculoskeletal, and renal complications. SSc patients often suffer from psychological impairments, such as depression, anxiety about disease progression, body image dissatisfaction and low self-esteem. The non-pharmacological interventions for the treatment of the psychological sequelae of systemic sclerosis currently available are limited and have shown poor efficacy. Well-Being Therapy (WBT) is a brief psychotherapy which has been manualized in 2016 and has shown efficacy in randomized clinical trials. It showed to be effective in decreasing the relapse rates of depression in adults, it showed to be effective in generalized anxiety disorder and in cyclothymia. No psychological treatment aimed at empowering the level of psychological well-being rather than at working on distress in SSc patients have been implemented although it was shown that such kind of interventions directly increase the level of psychological well-being and indirectly decrease the level of psychological distress (i.e., anxious and depressive symptoms) in subjects affected by chronic diseases. The aim of the present study is to evaluate the psychological status of SSc patients with specific attention to suffering and mental pain, and to test the efficacy of WBT in SSc subjects if compared to a control condition. Thus, sixty outpatients with a diagnosis of SSc will be enrolled and will receive WBT or the control condition.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Systemic Sclerosis
Keywords
systemic sclerosis, well-being, psychological distress, suffering, mental pain, well-being therapy, psychotherapy

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
This is a pilot study, designed as a randomized (1:1) controlled trial, comparing WBT vs a control condition. The patients will receive a baseline assessment to confirm the diagnosis of systemic sclerosis, then socio-demographic information, information on pharmacological/non-pharmacological treatments, on the history of medical diseases and on the psychological status will be collected. Thereafter, the subjects will be randomly assigned to WBT or to a control condition. The subjects will be re-assessed at the end of session 4, 8 of treatment, and at 6-month follow-up.
Masking
Participant
Masking Description
Participants will not be informed if they will receive WBT or the control condition. At the end of the study they will receive this information.
Allocation
Randomized
Enrollment
60 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Well-being therapy
Arm Type
Experimental
Arm Description
WBT will be used as the only non-pharmacological therapeutic strategy and 8 sessions will be delivered every other week with a duration of 60 minutes each. The manualized WBT will be used (Fava, 2016). Thus, the initial phase will be concerned with self-observation of psychological well-being. Once the instances of well-being will be properly recognized, the patient will be encouraged to identify thoughts, beliefs, and behaviors leading to premature interruption of well-being (intermediate phase). The final part will involve cognitive restructuring of dysfunctional dimensions of psychological well-being and meeting the challenge that optimal experiences may entail.
Arm Title
Control condition
Arm Type
Placebo Comparator
Arm Description
The control condition will include 8 every other week sessions based on Lifestyle and well-being National Institute for health and Care Excellence (NICE) guidelines (https://www.nice.org.uk/guidance/lifestyle-andwellbeing) and on World Health Organization 12 steps to healthy eating (http://www.euro.who.int/en/ health-topics/disease-prevention/nutrition/a-healthylifestyle). These sessions will inform participants about well-being and lifestyles which can influence it.
Intervention Type
Behavioral
Intervention Name(s)
Well-Being Therapy
Intervention Description
Well-Being Therapy (WBT) is a short-term psychotherapeutic strategy, that emphasizes self-observation with the use of a structured diary, interaction between patients and therapists and homework. WBT was based on the model of psychological well-being that was originally developed by Jahoda in 1958 and further refined by Ryff in 2014. The standard number of sessions is 8. The initial phase is concerned with self-observation of psychological well-being. Then, the patient is encouraged to identify thoughts, beliefs, and behaviors leading to premature interruption of wellbeing. The final part involves cognitive restructuring of dysfunctional dimensions of psychological well-being and meeting the challenge that optimal experiences may entail.
Intervention Type
Behavioral
Intervention Name(s)
Control condition
Intervention Description
The control condition will include 8 sessions that will inform participants about well-being and lifestyles which can influence it. They will be articulated as follows. Session 1: illustrating the concept of lifestyle and well-being. Session 2 and session 3: illustrating healthy eating and steps to healthy eating. Session 4: illustrating physical exercise and how it promotes health. Session 5: illustrating smoking and tobacco and how they can damage health. Session 6: illustrating alcohol and how it can damage health. Session 7: illustrating drug misuse and how it can damage health. Session 8: illustrating sexual health. No access to specific WBT ingredients will be allowed.
Primary Outcome Measure Information:
Title
Disability due to systemic sclerosis
Description
The primary outcome will be the level of disability due to systemic sclerosis, assessed via the Health Assessment Questionnaire Disability Index (minimum: 0, maximum: 40, the highest the score the highest the level of disability).
Time Frame
change from baseline to 6-month follow up
Secondary Outcome Measure Information:
Title
Psychiatric status
Description
Psychiatric status assessed via the Mini-International Neuropsychiatric Interview (no score applicable)
Time Frame
change from baseline to 6-month follow up
Title
Psychosomatic status
Description
Diagnostic Criteria for Psychosomatic Research-Revised Semi-Structured Interview (no score applicable)
Time Frame
change from baseline to 6-month follow up
Title
Well-being
Description
World Health Organization-Five Well-Being Index (min: 0, max: 25, the highest score corresponds to the lowest level of well-being)
Time Frame
change from baseline to 6-month follow up
Title
Psychological well-being
Description
the Psychological Well-Being Questionnaire (min: 0, max: 504, the highest score corresponds to the highest level of psychological well-being)
Time Frame
change from baseline to 6-month follow up
Title
Euthymia
Description
Euthymia Scale (min: 0, max: 60, the highest score corresponds to highest level of euthymia)
Time Frame
change from baseline to 6-month follow up
Title
Suffering
Description
Pictorial Representation of Illness and Self-Measure (min: 0, max: 30, the highest score corresponds to the lowest level of suffering)
Time Frame
change from baseline to 6-month follow up
Title
Psychological distress
Description
Symptom Questionnaire (min: 0, max: 92, the highest score corresponds to the highest level of psychological distress)
Time Frame
change from baseline to 6-month follow up
Title
Pain in the body
Description
Brief Pain Inventory (min: 0, max: 70, the highest score corresponds to highest level of pain)
Time Frame
change from baseline to 6-month follow up
Title
Mental pain
Description
Mental Pain Questionnaire (min: 0, max: 20, the highest score corresponds to the highest level of mental pain)
Time Frame
change from baseline to 6-month follow up
Title
Psychiatric symptoms
Description
Symptom Checklist-90-Revised (min: 0, max: 320, the highest score corresponds to the highest level of symptoms severity)
Time Frame
change from baseline to 6-month follow up
Title
Harmony
Description
Visual analouge scale (min: 0, max: 100, the highest score corresponds to the highest level of harmony)
Time Frame
change from baseline to 6-month follow up

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
75 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: able and interested in participating to the research, as proved by signed Informed consent; a diagnosis of SSc (limited or diffuse) according to LeRoy et al. (1998); age higher than 18 years Exclusion Criteria: co-occurrence of psychiatric disorder(s) according to the Diagnostic and Statistical Manual of mental disorders, 5th edition (American Psychiatric Association, 2013) as diagnosed via the Mini-International Neuropsychiatric Interview; currently under psychotherapy; change of the pharmacological treatment (including psychotropic medications) during the last three months. any other condition that, according to the Investigators' opinion, may alter the ability of the patient to follow study procedures.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Fiammetta Cosci, MD, PhD
Phone
0552755066
Ext
0039
Email
fiammetta.cosci@unifi.it
First Name & Middle Initial & Last Name or Official Title & Degree
Serena Guiducci, MD, Phd
Phone
3338144777
Ext
0039
Email
serenaguiducciphd@gmail.com
Facility Information:
Facility Name
Rheumtoi Unit, Academic Hospital Careggi
City
Florence
ZIP/Postal Code
50135
Country
Italy
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Serena Guiducci, MD
Phone
055 794111
Email
serena.guiducci@unifi.it
Facility Name
Fiammetta Cosci
City
Florence
Country
Italy
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Fiammetta Cosci, MD, PhD
Phone
0552755066
Ext
0039
Email
fiammetta.cosci@unifi.it

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Trial on Outpatients With Systemic Sclerosis Treated With Well-Being Therapy or With a Control Therapy

We'll reach out to this number within 24 hrs